NXERA PHARMA ENTERS INTO GLOBAL LICENSE AGREEMENT WITH ABBVIE FOR NXE0033744, A NOVEL EP4 RECEPTOR AGONIST FOR INFLAMMATORY BOWEL DISEASE

Reuters · 3d ago

Please log in to view news